Fig. 5
MiR-153 gain-of-function impairs presynaptic vesicle release in rat hippocampi. a Schematic diagram of stereotactic lentivirus injection into the CA1 region of the hippocampus. b Relative levels of miR-153 in the hippocampi of rats (PLevene = 0.069, one-way ANOVA: F = 39.14, P < 0.0001). n = 6. c Lenti-AMO-153 reversed the repression effect of lenti-pre-miR-153 on fEPSP in the CA3-CA1 pathway. χ2Mauchly = 484.594, P < 0.0001; Ftotal (14, 295) = 12.618, P < 0.0001, n = 7 for lenti-pre-miR-153 group, n = 8 for the lenti-AMO-153 and sham groups. d The fold change in the fEPSP amplitude following 60 μA current stimulation (PLevene = 0.620, one-way ANOVA: F = 3.993, P = 0.032). e Lenti-AMO-153 reversed the increased in the PPR induced by lenti-pre-miR-153. χ2Mauchly = 509.893, F(18, 433) = 18.968, P < 0.0001. Insertion: representive of EPSP traces. f Scatter dot plot showing the increased PPR with a 40 ms ISI in the lenti-pre-miR-153 injected rats compared with that in the lenti-NC-injected rats, and this increase in PPR was prevented by the coinjection with lenti-AMO-153 (PLevene = 0.186, one-way ANOVA: F = 17.454, P < 0.0001). g-j Lenti-pre-miR-153 repressed the protein levels of SNAP-25 (PLevene = 0.11, one-way ANOVA: F = 9.021, P = 0.001), VAMP-2 (PLevene = 0.352, one-way ANOVA: F = 13.824, P < 0.0001), syntaxin-1A (PLevene = 0.193, one-way ANOVA: F = 7.023, P = 0.002) and Syt1 (PLevene = 0.871, one-way ANOVA: F = 17.301, P < 0.0001) in the hippocampal synaptosomes. n = 6. *P < 0.05 vs lenti-NC; #P < 0.05 vs lenti-pre-miR-153